PROVECTUS ANNOUNCES PRESENTATION OF DATA FROM METASTATIC UVEAL MELANOMA COHORT OF PHASE 1 STUDY OF PV-10 IN LIVER CANCERS AT SMR ...
- Assessing adverse event and preliminary efficacy profiles of PV-10 as single-agent and in combination with immune checkpoint inhibition for treatment of liver metastases KNOXVILLE, TN, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today …